We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Novartis, Schering AG Suffer Setback on Cancer Drug
Novartis, Schering AG Suffer Setback on Cancer Drug
March 25, 2005
Novartis Pharmaceuticals and Schering AG have extended the timetable for developing one of their most important pipeline candidates — experimental colon-cancer drug PTK/ZK — after it failed to stop the growth of tumors in a Phase III study, the companies announced March 21.